Clinical trial · Interventional
Metformin in Stage IV Lung Adenocarcinoma
A Phase II Trial to Examine the Effect of Metformin on Plasma IL-6 Level in Patients With Advanced Non-Small Cell Lung Cancer
NCT01997775CI-TRIAL-00024116terminatedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Difficult enrollment
Summary
Brief summary (as posted)
The purpose of this study is to determine whether metformin is effective in lowering plasma IL-6 level and improving the treatment response in patients with non-small cell lung cancer
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| METFORMIN | Drug | Metformin | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- METFORMIN
- description
- For patients with stage IV lung adenocarcinoma and IL-6 level higher than 2.0 pg/ml after 2 cycles of standard treatment, metformin 500mg tid orally will be given.
- interventionNames
- Drug: METFORMIN
Primary outcomes (1)
- measure
- The change of plasma IL-6 level after the treatment with metformin
- timeFrame
- 12 weeks
Secondary outcomes (5)
- measure
- The objective response rate (RR)
- timeFrame
- 2 YEARS
- measure
- The progression free survival
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. Histologically or cytologically confirmed lung adenocarcinoma. 2. Stage IV disease as defined by AJCC 7th edition staging. 3. At least one measurable lesion (as defined by RECIST v1.1). 4. No prior radiotherapy, chemotherapy, surgery, target therapy, or immunotherapy for NSCLC. (Except the surgery for biopsy or port-A implantation, palliative localized radiotherapy for bone metastasis). 5. Age ≤ 80 years old and ≥ 20 years old. 6. ECOG performance status of 0-2. 7. Adequate organ function, including followings Bone marrow: Absolute neutrophil count (ANC) ≥ 1.5 x 10\^9/L; WBC ≥ 3.0 x 10\^9/L Platelet count ≥ 100 x 10\^9/L Hemoglobin ≥ 9g/dL Hepatic: Total bilirubin level ≤ 1.0 x UNL AST and ALT ≤ 3.0 x UNL; Renal: Creatinine level ≤ 1.5 mg/dL in men, ≤1.4 mg/dL in women; or Estimated CCr ≥ 60 mL/min. (CCr is estimated by Cockcroft-Gault formula, as appendix II)(CCr is estimated by Cockcroft-Gault formula) 8. Estimated life expectancy of at least 6 months. 9. Written (signed) Informed Consent. Exclusion Criteria: 1. With other primary malignancies, except those remain disease-free for 3 or more years after curative treatment, basal cell cancer of the skin or in situ cervical cancer. 2. Use of other anti-cancer therapy, including chemotherapy, target therapy, immunotherapy, radiotherapy, and hormone therapy. 3. Prior participation in any investigational drug study within 28 days. 4. Use of anti-IL-6 or IL-6-lowering agents. 5. Use of metformin in the past 6 months. 6. Poor controlled diabetes (HbA1c ≥ 8.0%). 7. Known hypersensitivity or intolerance to metformin. 8. Congestive heart failure with NYHA functional class II\~IV. 9. History of lactic acidosis. 10. Significant concurrent medical diseases, such as unstable angina, acute or recent myocardial infarction (\< 6 months before enrollment), COPD with frequent exacerbation, uncontrolled hypertension, or recent CVA (\< 6 months before enrollment). 11. Active uncontrolled infections or HIV infection. 12. Psychiatric disorders that would compromise the patient's compliance or decision. 13. Current or planned pregnancy, or breast feeding in women. 14. Poor compliance.
References
Publications (0)
Data not yet available
No reference posted for this study.